Homology scratches cash itch with manufacturing deal, bagging $130M to fund gene therapy trialsnews2022-01-28T11:31:06+00:00January 28th, 2022|FierceBiotech|
Taysha mulls tweaks to gene therapy trial after subject diesnews2022-01-27T13:45:05+00:00January 27th, 2022|FierceBiotech|
Neck and neck with Pfizer, Moderna gives first dose of omicron-specific booster in phase 2 trialnews2022-01-27T12:23:04+00:00January 27th, 2022|FierceBiotech|
9-year J&J science chief Stoffels to steer Galapagos’ rebound as CEOnews2022-01-26T21:35:37+00:00January 26th, 2022|FierceBiotech|
Septerna emerges with $100M to spark ‘second golden age’ of prolific drug target GPCR with pioneer as co-foundernews2022-01-26T20:34:52+00:00January 26th, 2022|FierceBiotech|
Incyte pulls FDA filing for cancer drug approval over confirmatory study, following Gilead out of the exitnews2022-01-26T11:49:10+00:00January 26th, 2022|FierceBiotech|
Gilead’s $4.9B oncology bet hit with partial clinical hold, forcing pause of pivotal trials and raising doubts about CD47news2022-01-26T10:49:20+00:00January 26th, 2022|FierceBiotech|
Gilead tags along again to support cell therapy biotech Kyverna in $85M fundraisingnews2022-01-25T19:00:32+00:00January 25th, 2022|FierceBiotech|
Pfizer, BioNTech launch trial for potential omicron-busting vaccinenews2022-01-25T14:29:17+00:00January 25th, 2022|FierceBiotech|
Sierra’s bet on Gilead castoff pays off, teeing up FDA filing for rival to Incyte-Novartis cancer drugnews2022-01-25T13:10:28+00:00January 25th, 2022|FierceBiotech|
